Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $64
Cantor Fitzgerald analyst Kristen Kluska maintains $PTC Therapeutics(PTCT.US)$ with a buy rating, and maintains the target price at $64.According to TipRanks data, the analyst has a success rate of 41
PTC Therapeutics Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ferroptosis Targeting Therapy Market Research & Clinical Trials Insight 2024 Featuring Kojin Therapeutics, MitoImmune Therapeutics, Prothegen, PTC Therapeutics, Sumitomo, and Tharimmune - ResearchAndMarkets.com
Baird Initiates Coverage On PTC Therapeutics With Outperform Rating, Announces Price Target of $44
Baird Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $44
Baird analyst Joel Beatty initiates coverage on $PTC Therapeutics(PTCT.US)$ with a buy rating, and sets the target price at $44.According to TipRanks data, the analyst has a success rate of 50.5%
PTC Appoints Rob Bernshteyn to Board of Directors
ClearPoint Neuro Shares Are Trading Higher After the Company Announced the Early Repayment of a $10 Million Convertible Note to PTC Therapeutics. Additionally, Lake Street Raised Its Price Target on the Stock From $11 to $15.
PTC Will Participate in Upcoming Investor Conferences
ClearPoint Neuro Repays $10 Million Convertible Note Early
ClearPoint Neuro Announces Full Early Repayment Of $10M Convertible Note To PTC Therapeutics Ahead Of January 2025 Maturity
PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says
Express News | PTC Therapeutics Inc : UBS Resumes Coverage With Buy Vs Neutral Rating; Target Price $47
PTC Therapeutics Price Target Announced at $47.00/Share by UBS
PTC Therapeutics Raised to Buy From Neutral by UBS
UBS Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $47
UBS analyst Eliana Merle initiates coverage on $PTC Therapeutics(PTCT.US)$ with a buy rating, and sets the target price at $47.According to TipRanks data, the analyst has a success rate of 42.3% and
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $37
Leerink Partners analyst Joseph Schwartz maintains $PTC Therapeutics(PTCT.US)$ with a hold rating, and sets the target price at $37.According to TipRanks data, the analyst has a success rate of 43.8%
PTC Therapeutics: Balancing Strong FY24 Guidance Against Regulatory Uncertainties
PTC Therapeutics, Inc. (NASDAQ:PTCT) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year